The latest price target for Minerva Surgical (OTCEM:UTRS) was reported by Piper Sandler on May 3, 2023. The analyst firm set a price target for $1.00 expecting UTRS to rise to within 12 months (a possible 8233.33% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Minerva Surgical (OTCEM:UTRS) was provided by Piper Sandler, and Minerva Surgical maintained their overweight rating.

There is no last upgrade for Minerva Surgical

The last downgrade for Minerva Surgical Inc happened on August 10, 2022 when JP Morgan changed their price target from N/A to N/A for Minerva Surgical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Minerva Surgical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Minerva Surgical was filed on May 3, 2023 so you should expect the next rating to be made available sometime around May 3, 2024.

While ratings are subjective and will change, the latest Minerva Surgical (UTRS) rating was a maintained with a price target of $5.00 to $1.00. The current price Minerva Surgical (UTRS) is trading at is $0.01, which is out of the analyst’s predicted range.